Tandem Diabetes Care (NASDAQ:TNDM) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a sell rating to a hold rating in a research report report published on Friday morning.

Several other research analysts also recently weighed in on TNDM. Citigroup upped their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a research note on Wednesday, April 3rd. Stifel Nicolaus raised shares of Tandem Diabetes Care from a hold rating to a buy rating and upped their price target for the company from $24.00 to $37.00 in a report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $37.00.

Tandem Diabetes Care Price Performance

Shares of TNDM stock opened at $30.43 on Friday. The firm has a fifty day simple moving average of $29.80 and a 200-day simple moving average of $24.80. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $40.92.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Equities analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors and hedge funds have recently modified their holdings of the business. RiverPark Advisors LLC bought a new position in shares of Tandem Diabetes Care in the 4th quarter worth about $27,000. MCF Advisors LLC lifted its position in Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares during the last quarter. State of Wyoming lifted its position in Tandem Diabetes Care by 45.8% in the 4th quarter. State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 258 shares during the last quarter. Signaturefd LLC lifted its position in Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after purchasing an additional 1,517 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after purchasing an additional 1,099 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.